The initiative is to provide research and development services for discovery and early drug development, Biocon said here on Wednesday.
Bristol-Myers Squibb will significantly increase the scope of its existing relationship with Syngene to develop integrated capabilities in medicinal chemistry, biology, drug metabolism and pharmaceutical development.
The partnership will include a dedicated research facility at the Biocon Park here which will eventually house a team of 400 scientists.
Biocon Chairperson, Kiran Mazumdar-Shaw, said, "The new research facility will take us forward in our evolution as a vaulable partner to the global pharma industry. Syngene has advanced capabilities in high-end services in discovery research." This one-of-its kind alliance in the biotech sector will leverage the current global demand for `bio-partnering' and access to top scientific talent in India for the overseas partner.
Chief Scientific Officer and President, Pharmaceutical Research, Bristol-Myers Squibb, Elliott Sigal, said, "This broad expansion of R&D in India will allow us to grow competitively and provide access to world-class talent to deliver and grow our robust product pipeline."
Syngene International is a custom research company that does research for client companies across the world and has multi-disciplinary skills in synthetic chemistry and molecular biology. It also leverages the convergence of information technology and biotechnology to conduct early stage drug discovery and was started in 1994.
No comments:
Post a Comment